Prostate cancer Posts on Medivizor

Evaluating the effectiveness and safety of salvage radiotherapy combined with hormone therapy in patients with biochemical recurrence of prostate cancer after prostate surgery.

Posted by Medivizor on Jul 7, 2024 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of salvage radiotherapy (RT) combined with hormone therapy in patients with biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy (RP; prostate removal surgery). This study found that salvage RT combined with hormone therapy was more effective than salvage RT...

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Jul 7, 2024 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide in combination with ADT improved the overall survival over the long term with...

Evaluating the long-term effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide in patients with metastatic prostate cancer starting androgen-deprivation therapy.

Posted by Medivizor on May 26, 2024 in Prostate cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) in patients with metastatic prostate cancer (PC) starting androgen-deprivation therapy (ADT). The data showed that enzalutamide and AA+P should not be combined...

Does statin use improve survival outcomes in men with advanced prostate cancer undergoing androgen deprivation therapy?

Posted by Medivizor on Sep 17, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the association between statin (cholesterol-lowering drugs) use and survival outcomes in men with advanced prostate cancer (PC) undergoing androgen deprivation therapy (ADT). The data showed that statin use improved the survival outcomes in these patients. Some background Metastatic prostate cancer (PC) is a form of...

Evaluating the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation with transurethral resection of the prostate in patients with prostate cancer.

Posted by Medivizor on Jul 30, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation (HIFU) with transurethral resection of the prostate (TURP) in patients with prostate cancer (PCa). The data showed that the combination treatment of whole-gland HIFU and TURP improved the urinary outcomes in these...

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 11, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Apr 30, 2023 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety of radium-223 dichloride (Xofigo) treatment in real-world patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that radium-223 dichloride treatment was well tolerated and reduced pain in real-world patients with mCRPC spread to the bone. Some...

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Posted by Medivizor on Apr 23, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of degarelix (Firmagon) with or without apalutamide (Erleada) before radical prostatectomy (RP; prostate surgery) in patients with high-risk prostate cancer (PC). The data showed that degarelix plus apalutamide significantly improved the pathological response in these patients. Some background...

Comparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Posted by Medivizor on Mar 26, 2023 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness of darolutamide (Nubeqa), apalutamide (Erleada), and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that darolutamide, apalutamide, and enzalutamide were similarly effective and improved survival outcomes compared to placebo...

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Mar 5, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Posted by Medivizor on Nov 22, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effects on patient-reported outcomes (PROs) of using olaparib (Lynparza) plus abiraterone (Zytiga) versus placebo plus abiraterone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study found that adding olaparib to abiraterone in these patients did not...

Comparing the effectiveness and safety of prostate-only versus pelvic radiotherapy for patients with prostate cancer spread to nearby lymph nodes.

Posted by Medivizor on Oct 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of whole-pelvis radiotherapy (WPRT) and prostate-only radiotherapy (PORT) in patients with node-positive prostate cancer (PC) (PC that has spread to nearby lymph nodes). The study found that WPRT improves survival without relapse in these patients, with more short-term...

Prostate cancer Posts on Medivizor

Evaluating the effectiveness and safety of salvage radiotherapy combined with hormone therapy in patients with biochemical recurrence of prostate cancer after prostate surgery.

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the long-term effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide in patients with metastatic prostate cancer starting androgen-deprivation therapy.

Does statin use improve survival outcomes in men with advanced prostate cancer undergoing androgen deprivation therapy?

Evaluating the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation with transurethral resection of the prostate in patients with prostate cancer.

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Comparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Comparing the effectiveness and safety of prostate-only versus pelvic radiotherapy for patients with prostate cancer spread to nearby lymph nodes.

Categories

Recent Posts

Archives

Prostate cancer Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email